VEGFA and posterior cortical atrophy: Clinical trials have shown some beneficial effects of targeting VEGF-A in patients with hormone-sensitive recurrent PCa, however, this was not observed in patients with castration-resistant PCa, and these therapies were also associated with adverse effects and high toxicity (8).